MedTrace Logo

Acute Study on Muscle Soreness, Damage, and Performance

NCT04230226 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-11-17

No results posted yet for this study

Summary

The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.

Conditions

  • Soreness, Muscle
  • Performance Enhancing Product Use
  • Damage Muscle

Interventions

DIETARY_SUPPLEMENT

Pre-workout plus and protein recovery plus

Study products consumed prior and after exercise

OTHER

Placebo

Placebo product consumed prior and after exercise

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • Pharmanex

    lead INDUSTRY

Principal Investigators

  • Abbie Smith-Ryan, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2020-09-16
Completion
2020-09-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04230226 on ClinicalTrials.gov